A phase 2, randomized, open-label, parallel, study with sotatercept in patients with anemia and low or intermediate-1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leukemia The primary objective of this study is to determine a safe, tolerable and effective dose of sotatercept that results in the greatest frequency of erythroid hematological improvement (HI-E) in patients...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical trial to see if the combination CC-486 plus fulvestrant is effective and safe, compared to fulvestrant alone, in patients with metastatic breast cancer that is estrogen receptor-positive and human epidermal growth factor receptor 2-negative To evaluate the efficacy of CC-486 in combination with fulvestrant relative to fulvestrant monotherapy, by estimation of the hazard ratio of progression free survival (PFS)

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with Beta-Thalassemia who require regular red blood cell tranfusions The primary objective of the study is: - To determine the proportion of subjects treated with luspatercept plus BSC versus placebo plus BSC who achieved erythroid response, defined as ≥ 33% reduction...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A large clinical study, for patients who have recently undergone surgery to remove some cancerous tissue from the pancreas, to compare post surgery treatment using nab-Paclitaxel and Gemcitibine or Gemcitibine alone To compare disease-free survival (DFS) between subjects randomized to nabpaclitaxel in combination with gemcitabine and subjects randomized to gemcitabine alone

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN’S LYMPHOMA • To determine the efficacy of lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Efficacy will be assessed by measuring the response rate, tumor control rate, dura...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to evaluate the effectiveness and safety of Apremilast in subjects with active psoriatic arthritis To evaluate the efficacy of apremilast 30 mg twice daily (BID) monotherapy, compared with placebo, over 24 weeks of treatment, with the primary analysis at Wk 16, in subjects with active psoriatic art...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

clinical study for pediatric patients with solid tumors that have come back after disappearing or that don’t respond to any treatment, designed to find the safest and most tolerable dose of nab ®-paclitaxel and to asses the preliminary efficacy of the treatment Phase I: determine the pediatric MTD/RP2D, safety and tolerability of nab-paclitaxel administered intravenously over 30min on Days 1, 8, and 15 of a 28-day cycle in patients ≥ 6 months and < 18 year...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase 3 study to evaluate safety and effectiveness of oral Apremilast (CC-10004) in patients with ankylosing spondylitis To evaluate the efficacy of apremilast 30 mg twice a day (BID), compared with placebo, in the reduction of signs and symptoms in subjects with active AS at 16 weeks of treatment

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 3 study of the safety and effectiveness of Apremilast versus placebo in patients with moderate to severe plaque psoriasis To evaluate the clinical efficacy of apremilast 30 mg BID, compared with placebo, in subjects with moderate to severe plaque psoriasis

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical study to determine how the drug CC-122 works in the body and to see if it is safe and if it works, when given alone, or in combination with Ibrutinib, or in combination with Obinutuzumab, for people who have Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Determine the safety of single agent CC-122 in subjects with relapsed/refractory CLL/SLL - Determine the safety and tolerability of the combination of CC-122 and ibrutinib and determine the RP2D o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune